EXHIBIT 10.18 [Danka Logo] November 20, 2000 Mr. Michael Gifford 11216 Tamiami Trail North PMB334 Naples, FL 34110 Dear Michael: This Letter will confirm the agreement between you and the Danka Business Systems, PLC, Board of Directors, to perform the...Ceo Agreement • April 17th, 2001 • Danka Business Systems PLC • Wholesale-professional & commercial equipment & supplies
This Letter will confirm the agreement between you and the Danka Business Systems, PLC, Board of Directors, to perform the duties of Chief Executive Officer of the Company until a permanent Chief Executive Officer is found or this Letter Agreement is otherwise terminated by either party. Your powers and duties for the Company shall be those powers and duties customary to the Chief Executive Officer in similar publicly held corporations and you will report to the Board of Directors.
Ocera Therapeutics, Inc.Ceo Agreement • August 14th, 2013 • Ocera Therapeutics, Inc. • Pharmaceutical preparations
The purpose of this letter agreement is to set forth the principal terms of the agreement that we have reached with respect to you serving as the Chief Executive Officer of Ocera Therapeutics, Inc., a Delaware corporation (the "Company") on an interim basis. That agreement is as follows:
MEDICAL CARE TECHNOLOGIES INC. NING WU CEO AGREEMENTCeo Agreement • April 27th, 2012 • Medical Care Technologies Inc. • Metal mining • Nevada
CEO AgreementCeo Agreement • April 28th, 2022 • Ads-Tec Energy Public LTD Co • Miscellaneous transportation equipment
ads-tec Energy GmbH, Heinrich-Hertz-Straße 1, 72622 Nürtingen, represented by its shareholder ads-tec Energy PLC, this one represented by Prof. Kurt Lauk as its chairman of board of directors.
CEO Contract 12/15/2010 11:04 AM11/24/2010 8:25 a.m.Ceo Agreement • January 7th, 2011 • California
between the PALO VERDE HEALTH CARE DISTRICT, a governmental entity, by and through its Board of Directors (hereinafter referred to as the “District”) and PETER KLUNE (hereinafter referred to as “Employee”).
ContractCeo Agreement • September 4th, 2009 • Discovery Laboratories Inc /De/ • Biological products, (no disgnostic substances) • Pennsylvania
This Agreement (“Agreement”) shall be effective as of August 13, 2009, by and between DISCOVERY LABORATORIES, INC., a Delaware corporation (“Company”) and W. THOMAS AMICK, Chairman of the Board of Directors of the Company (“Amick”).
CEO AgreementCeo Agreement • November 26th, 2021 • European Sustainable Growth Acquisition Corp. • Blank checks
Thomas Speidel has been working as managing director for ads-tec Energy GmbH in Nurtingen (and its future subsidiaries and affiliated companies) as well as for ads-tec Holding GmbH and its subsidiaries since many years. The ads-tec group is continuing to develop at a highly dynamic pace. Based on the excellent cooperation to date, Thomas Speidel is now also to take on further tasks with an even higher level of responsibility. In this connection the parties agree the following, expressly maintaining all other provisions set out in the Managing Director’s Contract between Thomas Speidel and ads-tec Holding GmbH together with any amendment agreements, these shall remain unaffected by this CEO agreement:
Attachment 4 to CEO Agreement No. CTGG1 19-3223 between the CEO and ChargePoint, Inc.Ceo Agreement • April 10th, 2019
AMENDED AND RESTATED AGREEMENTCeo Agreement • March 21st, 2002 • Idexx Laboratories Inc /De • In vitro & in vivo diagnostic substances
This Agreement, dated as of October 17, 2001, amends and restates in its entirety the Agreement dated as of August 26, 1999 between IDEXX Laboratories, Inc. ("IDEXX") and David E. Shaw ("Shaw") regarding Shaw's reappointment as Chief Executive Officer of IDEXX, and the planned recruitment and appointment of a person to succeed Shaw as such Chief Executive Officer. In consideration of Shaw's willingness to serve as Chief Executive Officer pending the identification and appointment of a successor (the "Succession"), and to serve as Executive Chairman for a period of time after the Succession, and for other good and valuable consideration, the parties agree as follows:
AGREEMENTCeo Agreement • November 12th, 1999 • Idexx Laboratories Inc /De • In vitro & in vivo diagnostic substances
UNOFFICIAL TRANSLATION FROM FINNISH CEO AGREEMENTCeo Agreement • March 11th, 2016 • Biotie Therapies Corp. • Pharmaceutical preparations
Biotie Therapies Corp. (the “Company”) and Timo Veromaa (the “President and CEO”) have today entered into the following CEO Agreement (the “Agreement”).
